Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802)

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer

• Publication date

  2008-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.23503PMID 18459175PMCID PMC2674559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

  2007cited by this paper
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

  2006cited by this paper
• A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.

  2006cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients

  2006cited by this paper
• Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

  2006cited by this paper
• Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.

  2004cited by this paper
• Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

  2002cited by this paper
• Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896)

  2002cited by this paper
• Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.

  2000cited by this paper
• Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.

  2000cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper
• Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

  1997cited by this paper
• Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

  1997cited by this paper
• Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

  1997cited by this paper
• LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

  1997cited by this paper
• Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

  1994cited by this paper

• Chemotherapeutic Agents for Urologic Oncology: Basic Principles

  2020cites this paper
• SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

  2018cites this paper
• Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report

  2017cites this paper
• The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents

  2016cites this paper
• The safety and efficacy of gemcitabine for the treatment of bladder cancer

  2016cites this paper
• Phase II study of dual phosphoinositol‐3‐kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

  2016cites this paper
• Pemetrexed in treating patients with metastatic bladder cancer.

  2015cites this paper
• First-line treatment of metastatic disease: cisplatin-ineligible patients.

  2015cites this paper
• Conditional Survival in de novo Metastatic Urothelial Carcinoma

  2015cites this paper
• Systemic therapy for bladder cancer - a medical oncologist's perspective.

  2014cites this paper
• Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)

  2014influential citation
• Optimizing systemic therapy for bladder cancer.

  2013cites this paper
• Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma

  2011cites this paper
• Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

  2011cites this paper
• Personalized therapy for urothelial cancer: review of the clinical evidence.

  2011cites this paper
• First- and second-line therapy for metastatic urothelial carcinoma of the bladder.

  2011cites this paper
• Current treatment of metastatic bladder cancer and future directions

  2011cites this paper
• Bladder cancer.

  2011cites this paper
• Prise en charge du patient métastatique dans le cancer de la vessie

  2010cites this paper
• Antifolate inhibitors of thymidylate synthase as anticancer drugs.

  2010cites this paper
• Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.

  2010cites this paper
• [Treatment strategies for metastatic patients in bladder cancer].

  2010cites this paper
• Second-line therapy in bladder cancer

  2009cites this paper
• Chemotherapie des Harnblasenkarzinoms

  2003cites this paper
• Bladder cancer

  2000cites this paper